Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 282


Ag85B synergizes with ESAT-6 to induce efficient and long-term immunity of C57BL/6 mice primed with recombinant Bacille Calmette-Guerin.

Liu W, Xu Y, Yan J, Shen H, Yang E, Wang H.

Exp Ther Med. 2017 Jan;13(1):208-214. doi: 10.3892/etm.2016.3944.


Mycobacterium tuberculosis Rv2882c Protein Induces Activation of Macrophages through TLR4 and Exhibits Vaccine Potential.

Choi HG, Choi S, Back YW, Park HS, Bae HS, Choi CH, Kim HJ.

PLoS One. 2016 Oct 6;11(10):e0164458. doi: 10.1371/journal.pone.0164458.


Comparative Analysis of Human B Cell Epitopes Based on BCG Genomes.

Li M, Liu H, Zhao X, Wan K.

Biomed Res Int. 2016;2016:3620141. doi: 10.1155/2016/3620141.


Mycobacterial L-forms are found in cord blood: A potential vertical transmission of BCG from vaccinated mothers.

Markova N, Slavchev G, Djerov L, Nikolov A, Dimova T.

Hum Vaccin Immunother. 2016 Oct 2;12(10):2565-2571. doi: 10.1080/21645515.2016.1193658.


The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against Mycobacterium tuberculosis.

Prados-Rosales R, Carreño LJ, Weinrick B, Batista-Gonzalez A, Glatman-Freedman A, Xu J, Chan J, Jacobs WR Jr, Porcelli SA, Casadevall A.

J Infect Dis. 2016 Aug 1;214(3):426-37. doi: 10.1093/infdis/jiw153.


Isolation of Nontuberculous Mycobacteria from the Environment of Ghanian Communities Where Buruli Ulcer Is Endemic.

Aboagye SY, Danso E, Ampah KA, Nakobu Z, Asare P, Otchere ID, Röltgen K, Yirenya-Tawiah D, Yeboah-Manu D.

Appl Environ Microbiol. 2016 Jun 30;82(14):4320-9. doi: 10.1128/AEM.01002-16.


Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis.

Nandakumar S, Kannanganat S, Dobos KM, Lucas M, Spencer JS, Amara RR, Plikaytis BB, Posey JE, Sable SB.

Sci Rep. 2016 May 13;6:25837. doi: 10.1038/srep25837.


The mc2-CMX vaccine induces an enhanced immune response against Mycobacterium tuberculosis compared to Bacillus Calmette-Guérin but with similar lung inflammatory effects.

Oliveira FM, Trentini MM, Junqueira-Kipnis AP, Kipnis A.

Mem Inst Oswaldo Cruz. 2016 Apr;111(4):223-31. doi: 10.1590/0074-02760150411.


TLR Agonist Augments Prophylactic Potential of Acid Inducible Antigen Rv3203 against Mycobacterium tuberculosis H37Rv in Experimental Animals.

Mohammad O, Kaur J, Singh G, Faisal SM, Azhar A, Rauf MA, Gupta UD, Gupta P, Pal R, Zubair S.

PLoS One. 2016 Mar 29;11(3):e0152240. doi: 10.1371/journal.pone.0152240.


Why don't we have an effective tuberculosis vaccine yet?

Davenne T, McShane H.

Expert Rev Vaccines. 2016 Aug;15(8):1009-13. doi: 10.1586/14760584.2016.1170599.


Current status of new tuberculosis vaccine in children.

Pang Y, Zhao A, Cohen C, Kang W, Lu J, Wang G, Zhao Y, Zheng S.

Hum Vaccin Immunother. 2016 Apr 2;12(4):960-70. doi: 10.1080/21645515.2015.1120393.


Construction of eukaryotic expression vectors encoding CFP-10 and ESAT-6 genes and their potential in lymphocyte proliferation.

Torabi A, Tahmoorespour M, Vahedi F, Mosavari N, Nassiri M.

Rep Biochem Mol Biol. 2013 Oct;2(1):35-41.


Inhibition of Mycobacterium-RmlA by Molecular Modeling, Dynamics Simulation, and Docking.

Harathi N, Pulaganti M, Anuradha CM, Kumar Chitta S.

Adv Bioinformatics. 2016;2016:9841250. doi: 10.1155/2016/9841250.


The Mycobacterium bovis BCG prime-Rv0577 DNA boost vaccination induces a durable Th1 immune response in mice.

Gu D, Chen W, Mi Y, Gong X, Luo T, Bao L.

Acta Biochim Biophys Sin (Shanghai). 2016 Apr;48(4):385-90. doi: 10.1093/abbs/gmw010.


On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines.

Arregui S, Sanz J, Marinova D, Martín C, Moreno Y.

PeerJ. 2016 Feb 11;4:e1513. doi: 10.7717/peerj.1513.


Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection.

Xu ZZ, Chen X, Hu T, Meng C, Wang XB, Rao Y, Zhang XM, Yin YL, Pan ZM, Jiao XA.

Front Cell Infect Microbiol. 2016 Jan 28;6:3. doi: 10.3389/fcimb.2016.00003.


A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.

Minhinnick A, Satti I, Harris S, Wilkie M, Sheehan S, Stockdale L, Manjaly Thomas ZR, Lopez-Ramon R, Poulton I, Lawrie A, Vermaak S, Le Vert A, Del Campo J, Hill F, Moss P, McShane H.

Vaccine. 2016 Mar 8;34(11):1412-21. doi: 10.1016/j.vaccine.2016.01.062.


The Secreted Protein Rv1860 of Mycobacterium tuberculosis Stimulates Human Polyfunctional CD8+ T Cells.

Satchidanandam V, Kumar N, Biswas S, Jumani RS, Jain C, Rani R, Aggarwal B, Singh J, Kotnur MR, Sridharan A.

Clin Vaccine Immunol. 2016 Apr 4;23(4):282-93. doi: 10.1128/CVI.00554-15.


A review of clinical models for the evaluation of human TB vaccines.

O'Shea MK, McShane H.

Hum Vaccin Immunother. 2016 May 3;12(5):1177-87. doi: 10.1080/21645515.2015.1134407.


Non-tuberculous mycobacteria: baseline data from three sites in Papua New Guinea, 2010-2012.

Ley S, Carter R, Millan K, Phuanukoonnon S, Pandey S, Coulter C, Siba P, Beck HP.

Western Pac Surveill Response J. 2015 Nov 24;6(4):24-9. doi: 10.5365/WPSAR.2015.6.2.004.

Items per page

Supplemental Content

Support Center